A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.

Rutika Mehta,Sarbajit Mukherjee,Kelsey Klute,Haeseong Park,Uqba Khan,Sahrish Khan,Carina Puello,Sabrina Machado,Paul J. Christos,Nicholas J. Sanfilippo,Manish A. Shah

A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.

2021

Rutika Mehta
Sarbajit Mukherjee
Kelsey Klute
Haeseong Park
Uqba Khan
Sahrish Khan
Carina Puello
Sabrina Machado
Paul J. Christos
Nicholas J. Sanfilippo
Manish A. Shah

TPS4157Background: GEA remains incurable and novel therapies are needed. Studies have shown that cytotoxic chemotherapy can enhance antigenicity of tumors, leading to the recent practice changing s...

Keywords:

cytotoxic chemotherapy
FOLFOX
Oncology
Nivolumab
Chemotherapy
Medicine
Internal medicine
first line treatment
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations